Patient Access
December 7, 2020
Alnylam Releases 2nd Annual Patient Access Philosophy Report
The 2020 Alnylam Patient Access Philosophy Report details Alnylam's progress against key metrics related to patient access to its innovative RNAi therapeutics.
Read More ›
October 1, 2020
A New European Biotech Social Pact
The European Pact builds on Alnylam’s own pledge, encouraging biotech companies to be a force for good in partnering with European authorities, citizens and...
Read More ›
September 2, 2020
With Innovation in Market Access, European Patients Can Fully Experience Biotech’s Transfo ...
What’s needed is a larger measure of creativity, flexibility and coordination around market access. This must become the new baseline environment in which...
Read More ›
December 12, 2019
Building Bridges to Support Patients’ Care
Supporting patients and their caregivers by facilitating access to innovative treatments is at the core of our Patient Access Philosophy.
Read More ›
September 9, 2019
Alnylam's Patient Access Philosophy - Our Progress
Nearly two years ago – before we launched our first product – we made a commitment to strive toward broad patient access to our medicines. In our view...
Read More ›
FOLLOW US
